- Home
- PRO vs KALV Comparison
PRO vs KALV Comparison
Compare PRO & KALV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PRO
- KALV
- Stock Information
- Founded
- PRO 1985
- KALV N/A
- Country
- PRO United States
- KALV United States
- Employees
- PRO N/A
- KALV N/A
- Industry
- PRO EDP Services
- KALV Biotechnology: Pharmaceutical Preparations
- Sector
- PRO Technology
- KALV Health Care
- Exchange
- PRO Nasdaq
- KALV Nasdaq
- Market Cap
- PRO 761.5M
- KALV 796.4M
- IPO Year
- PRO 2007
- KALV N/A
- Fundamental
- Price
- PRO $15.85
- KALV $13.38
- Analyst Decision
- PRO Strong Buy
- KALV Strong Buy
- Analyst Count
- PRO 9
- KALV 8
- Target Price
- PRO $26.89
- KALV $26.43
- AVG Volume (30 Days)
- PRO 628.5K
- KALV 984.5K
- Earning Date
- PRO 10-28-2025
- KALV 09-11-2025
- Dividend Yield
- PRO N/A
- KALV N/A
- EPS Growth
- PRO N/A
- KALV N/A
- EPS
- PRO N/A
- KALV N/A
- Revenue
- PRO $342,708,000.00
- KALV $1,426,000.00
- Revenue This Year
- PRO $10.33
- KALV N/A
- Revenue Next Year
- PRO $10.76
- KALV $213.43
- P/E Ratio
- PRO N/A
- KALV N/A
- Revenue Growth
- PRO 7.96
- KALV N/A
- 52 Week Low
- PRO $13.61
- KALV $7.30
- 52 Week High
- PRO $29.84
- KALV $17.28
- Technical
- Relative Strength Index (RSI)
- PRO 56.12
- KALV 43.21
- Support Level
- PRO $14.49
- KALV $13.26
- Resistance Level
- PRO $15.55
- KALV $14.25
- Average True Range (ATR)
- PRO 0.55
- KALV 1.03
- MACD
- PRO 0.03
- KALV -0.15
- Stochastic Oscillator
- PRO 85.67
- KALV 3.70
About PRO PROS Holdings Inc.
Pros Holdings Inc provides software solutions that optimize shopping and selling experiences for both business-to-business and business-to-consumer companies across industry verticals in more than nearly 80 countries. Its PROS Platform is designed to help businesses create, optimize and market available offers and handle orders through both first- and third-party digital channels. The firm generates key revenue form the United States of America, Germany, The rest of Europe, Africa, Asia-Pacific, and Middle East regions.
About KALV KalVista Pharmaceuticals Inc.
KalVista Pharmaceuticals Inc is a pharmaceutical company developing and delivering oral therapies for individuals affected by rare diseases with unmet needs. The company applies its knowledge in the kallikrein-kinin system (KKS) and oral drug discovery to develop small-molecule protease inhibitor medicines to address the needs of patients with diseases driven by plasma kallikrein and Factor XIIa. Its FDA-approved product EKTERLY (sebetralstat) is a novel, orally delivered, small-molecule plasma kallikrein inhibitor for the treatment of acute attacks of hereditary angioedema (HAE) in adult and pediatric patients aged twelve years and older.